Arrowstreet Capital Limited Partnership boosted its holdings in Retrophin Inc (NASDAQ:RTRX) by 185.8% during the 4th quarter, HoldingsChannel reports. The fund owned 34,014 shares of the biopharmaceutical company’s stock after buying an additional 22,114 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Retrophin were worth $717,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in RTRX. Trexquant Investment LP bought a new position in Retrophin in the 3rd quarter valued at approximately $203,000. Dynamic Technology Lab Private Ltd bought a new position in Retrophin in the 3rd quarter valued at approximately $212,000. Campbell & CO Investment Adviser LLC bought a new position in Retrophin in the 3rd quarter valued at approximately $249,000. Teacher Retirement System of Texas bought a new position in Retrophin in the 4th quarter valued at approximately $256,000. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Retrophin in the 3rd quarter valued at approximately $349,000.
Several equities analysts have recently weighed in on RTRX shares. BidaskClub cut Retrophin from a “buy” rating to a “hold” rating in a report on Saturday, December 30th. ValuEngine cut Retrophin from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd. Finally, Zacks Investment Research cut Retrophin from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $44.00.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/3258739/arrowstreet-capital-limited-partnership-buys-22114-shares-of-retrophin-inc-rtrx.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.